Search
Formoterol
go.drugbank.com/drugs/DB00983ApprovedInvestigational[A189528] A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration … of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication.
Mixtures: SYMBICORT TUR160UG/D 120ED, SYMBICORT TURBO160/4.5UG/DProducts: FORMOTEROLHEXALEASY 12UG/DCloxazolam
go.drugbank.com/drugs/DB01553ExperimentalThe usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety. … Cloxazolam is a benzodiazepine with anxiolytic, sedative/hypnotic, muscle relaxant, and antiepileptic effects.
Selisistat
go.drugbank.com/drugs/DB13978InvestigationalEnhances p53 acetylation in response to DNA damaging agents.
Allovectin-7
go.drugbank.com/drugs/DB17439InvestigationalAllovectin-7 or allovectin-7(r) is a lipid complex that contains the DNA sequences encoding HLA-B7 and beta-2 microglobulin.
Cinalukast
go.drugbank.com/drugs/DB00587ExperimentalUsed in the treatment of asthma, cinalukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway.
Pimicotinib
go.drugbank.com/drugs/DB18972Investigational[L53748] Pimicotinib was granted Fast Track Designation in December 2023 by the FDA. [L53753]
Repotrectinib
go.drugbank.com/drugs/DB16826ApprovedInvestigational[A262066] On November 15th, 2023, the FDA approved repotrectinib under the brand name Augtyro for the treatment of locally advanced or metastatic ROS1-Positive NSCLC. … Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the
Synonyms: (3R,6S,)-45-FLUORO-3,6-DIMETHYL-5-OXA-2,8-DIAZA-1(5,3)-PYRAZOLO(1,5-A)PYRIMIDINA-4(1,2)-BENZENANONAPHAN-9-ONEVamorolone
go.drugbank.com/drugs/DB15114ApprovedInvestigationalVamorolone is a novel and fully synthetic glucocorticoid developed by Santhera Pharmaceuticals. … [L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age.
Tyrothricin
go.drugbank.com/drugs/DB13503ApprovedWithdrawnNevertheless, as tyrothricin is both cytolytic and hemolytic, it does demonstrate systemic toxicity [L4019, L4021, L4022], although certain formulations that are safe for human use like throat lozenges do … and 40% neutral linear gramicidins (where valine-gramicidin A is often the major gramicidin present, although the mixture composition can vary) [L4019, L4021, L4022].
Interferon alfacon-1
go.drugbank.com/drugs/DB00069ApprovedWithdrawnFour additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology. … This protein has a molecular weight of 19,434 daltons.